From b4640cf2185382c6e5c2f572de8c77d07d413b6d Mon Sep 17 00:00:00 2001 From: Teleo Agents Date: Wed, 8 Apr 2026 04:22:12 +0000 Subject: [PATCH] vida: extract claims from 2026-04-08-lancet-glp1-metabolic-rebound - Source: inbox/queue/2026-04-08-lancet-glp1-metabolic-rebound.md - Domain: health - Claims: 1, Entities: 0 - Enrichments: 0 - Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5) Pentagon-Agent: Vida --- ...rse-within-28-52-weeks-of-discontinuation.md | 17 +++++++++++++++++ 1 file changed, 17 insertions(+) create mode 100644 domains/health/glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation.md diff --git a/domains/health/glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation.md b/domains/health/glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation.md new file mode 100644 index 000000000..9598aeb90 --- /dev/null +++ b/domains/health/glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation.md @@ -0,0 +1,17 @@ +--- +type: claim +domain: health +description: "Discontinuation produces rapid rebound: 40% of semaglutide weight loss regained in 28 weeks, 50% of tirzepatide loss in 52 weeks, with cardiovascular and glycemic markers also reversing" +confidence: likely +source: Tzang et al., Lancet eClinicalMedicine meta-analysis of 18 RCTs (n=3,771) +created: 2026-04-08 +title: GLP-1 receptor agonists require continuous treatment because metabolic benefits reverse within 28-52 weeks of discontinuation +agent: vida +scope: causal +sourcer: Tzang et al. (Lancet eClinicalMedicine) +related_claims: ["[[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]", "[[SDOH interventions show strong ROI but adoption stalls because Z-code documentation remains below 3 percent and no operational infrastructure connects screening to action]]"] +--- + +# GLP-1 receptor agonists require continuous treatment because metabolic benefits reverse within 28-52 weeks of discontinuation + +Meta-analysis of 18 randomized controlled trials (n=3,771) demonstrates that GLP-1 receptor agonist benefits require continuous treatment. After discontinuation, mean weight gain was 5.63 kg, with 40%+ of semaglutide-induced weight loss regained within 28 weeks and 50%+ of tirzepatide loss regained within 52 weeks. Nonlinear meta-regression predicts return to pre-treatment weight levels within <2 years. Critically, the rebound extends beyond weight: waist circumference, BMI, systolic blood pressure, HbA1c, fasting plasma glucose, cholesterol, and blood pressure all deteriorate post-discontinuation. STEP-10 and SURMOUNT-4 trials confirmed substantial weight regain, glycemic control deterioration, and reversal of lipid/blood pressure improvements. While individualized dose-tapering can limit (but not prevent) rebound, no reliable long-term strategy for weight management after cessation exists. This continuous-treatment dependency means GLP-1 efficacy at the population level requires permanent access infrastructure, not just drug availability. Coverage gaps of 3-6 months—common under Medicaid redetermination cycles—can fully reverse therapeutic benefits that took months to achieve.